ATE517909T1 - Effizientes gewinnungsverfahren von korrekterweise rückgefalteten proteinen - Google Patents

Effizientes gewinnungsverfahren von korrekterweise rückgefalteten proteinen

Info

Publication number
ATE517909T1
ATE517909T1 AT02725004T AT02725004T ATE517909T1 AT E517909 T1 ATE517909 T1 AT E517909T1 AT 02725004 T AT02725004 T AT 02725004T AT 02725004 T AT02725004 T AT 02725004T AT E517909 T1 ATE517909 T1 AT E517909T1
Authority
AT
Austria
Prior art keywords
extraction
efficient process
refolded proteins
correctly refolded
proteins
Prior art date
Application number
AT02725004T
Other languages
English (en)
Inventor
Helmut Sassenfeld
Richard Remmele
Rebecca McCOY
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23033913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE517909(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE517909T1 publication Critical patent/ATE517909T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)
  • Measurement Of Radiation (AREA)
AT02725004T 2001-02-23 2002-02-22 Effizientes gewinnungsverfahren von korrekterweise rückgefalteten proteinen ATE517909T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27103301P 2001-02-23 2001-02-23
PCT/US2002/005645 WO2002068455A2 (en) 2001-02-23 2002-02-22 Efficient recovery of correctly refolded proteins

Publications (1)

Publication Number Publication Date
ATE517909T1 true ATE517909T1 (de) 2011-08-15

Family

ID=23033913

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02725004T ATE517909T1 (de) 2001-02-23 2002-02-22 Effizientes gewinnungsverfahren von korrekterweise rückgefalteten proteinen

Country Status (20)

Country Link
US (2) US7157557B2 (de)
EP (1) EP1366062B1 (de)
JP (1) JP2005505494A (de)
KR (1) KR20040052481A (de)
CN (1) CN1547586A (de)
AT (1) ATE517909T1 (de)
AU (1) AU2002255600B2 (de)
BG (1) BG108087A (de)
CA (1) CA2438094C (de)
CZ (1) CZ20032208A3 (de)
EE (1) EE200300408A (de)
ES (1) ES2370235T3 (de)
HU (1) HUP0303246A2 (de)
IL (1) IL157446A0 (de)
MX (1) MXPA03007563A (de)
PL (1) PL374045A1 (de)
RU (1) RU2316563C2 (de)
SK (1) SK10472003A3 (de)
WO (1) WO2002068455A2 (de)
ZA (1) ZA200305909B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005505494A (ja) * 2001-02-23 2005-02-24 イミュネックス・コーポレーション 活性タンパク質の回収増加
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
WO2006060083A1 (en) * 2004-10-22 2006-06-08 Amgen Inc. Methods for refolding polypeptides
JP5553963B2 (ja) 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
JP2008528006A (ja) * 2005-01-28 2008-07-31 アポロ ライフ サイエンシズ リミテッド 分子およびそのキメラ分子
AU2006247039B2 (en) 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
EP1893632B1 (de) * 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selektive reduktion und derivatisierung manipulierter faktor vii proteine mit mindestens einem nichtnativen zystein
NZ568809A (en) 2005-12-22 2011-08-26 Genentech Inc Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
US20080125580A1 (en) 2006-07-14 2008-05-29 Genentech, Inc. Refolding of Recombinant Proteins
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
MX2010002683A (es) * 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
EA020621B1 (ru) 2009-06-22 2014-12-30 Амген Инк. Рефолдинг белков с использованием химически контролируемого окислительно-восстановительного состояния
LT3660032T (lt) 2009-06-25 2026-02-25 Amgen Inc. Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
DK2483289T4 (da) 2009-10-02 2025-05-19 Biogen Ma Inc Fremgangsmåder til forebyggelse og fjernelse af trisulfidbindinger
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
EP2673296B1 (de) 2011-02-07 2018-10-24 Cerenis Therapeutics Holding SA Lipoproteinkomplexe, ihre herstellung und verwendung
EP2718328A4 (de) 2011-06-08 2014-12-24 Acceleron Pharma Inc Zusammensetzungen und verfahren zur erhöhung der halbwertszeit von serum
EP3628327A1 (de) 2011-06-24 2020-04-01 The Regents of the University of Colorado, A Body Corporate Zusammensetzungen, verfahren und verwendung für alpha-1-antitrypsin-fusionsmoleküle
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US9353165B2 (en) * 2012-07-25 2016-05-31 Grifols, S.A. Purification of cell culture derived alpha1 protease inhibitor
BR112015002091A2 (pt) 2012-08-02 2017-12-12 Hoffmann La Roche método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
EA031324B1 (ru) 2012-09-11 2018-12-28 Кохерус Байосайенсис, Инк. Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода
SG10201709131UA (en) 2013-03-08 2017-12-28 Genzyme Corp Continuous purification of therapeutic proteins
TWI671312B (zh) 2014-01-17 2019-09-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
HK40046210A (en) 2018-08-31 2021-10-29 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
WO2022140389A1 (en) 2020-12-22 2022-06-30 Amgen Inc. Cell culture method
WO2025128536A1 (en) * 2023-12-14 2025-06-19 Genentech, Inc. Disulfide isoform modulation
CN118047854B (zh) * 2024-02-26 2024-08-02 武汉鹰达生物科技有限公司 一种人载脂蛋白a-i的分离纯化方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
AU626524B2 (en) 1987-05-29 1992-08-06 Bristol-Myers Squibb Company Cloning and expression of simian transforming growth factor- beta 1
US4970067A (en) * 1988-12-12 1990-11-13 Helene Curtis, Inc. Method and composition to condition hair and impart semi-permanent hair set retention properties
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
AU648214B2 (en) 1991-12-31 1994-04-14 Lucky Limited Recombinant gene coding for human alpha interferon and expression vector thereof, etc.
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU685835B2 (en) * 1993-08-04 1998-01-29 Novartis Ag High molecular weight desulphatohirudin
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
AU2603995A (en) 1994-05-25 1995-12-18 University Of Nebraska Board Of Regents Biologically active glycoprotein hormones produced in procaryotic cells
JPH09508140A (ja) * 1994-07-22 1997-08-19 エフ・ホフマン−ラ ロシュ アーゲー キメラｔｎｆ結合タンパク質を含有する医薬組成物
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
FR2803303B1 (fr) * 2000-01-04 2002-05-10 Aventis Pasteur Glycoproteine d'enveloppe du vih modifiee chimiquement
JP2005505494A (ja) * 2001-02-23 2005-02-24 イミュネックス・コーポレーション 活性タンパク質の回収増加

Also Published As

Publication number Publication date
PL374045A1 (en) 2005-09-19
EP1366062B1 (de) 2011-07-27
HUP0303246A2 (hu) 2003-12-29
HK1059267A1 (en) 2004-06-25
WO2002068455A2 (en) 2002-09-06
ZA200305909B (en) 2004-06-04
WO2002068455A3 (en) 2003-09-18
AU2002255600B2 (en) 2008-01-24
SK10472003A3 (sk) 2004-03-02
EP1366062A2 (de) 2003-12-03
US7544784B2 (en) 2009-06-09
RU2316563C2 (ru) 2008-02-10
ES2370235T3 (es) 2011-12-13
KR20040052481A (ko) 2004-06-23
EE200300408A (et) 2003-12-15
BG108087A (bg) 2005-04-30
CN1547586A (zh) 2004-11-17
MXPA03007563A (es) 2003-12-11
CA2438094C (en) 2011-10-11
US20070270577A1 (en) 2007-11-22
RU2003127830A (ru) 2005-04-10
IL157446A0 (en) 2004-03-28
JP2005505494A (ja) 2005-02-24
US7157557B2 (en) 2007-01-02
CZ20032208A3 (cs) 2004-01-14
US20020182665A1 (en) 2002-12-05
CA2438094A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
ATE517909T1 (de) Effizientes gewinnungsverfahren von korrekterweise rückgefalteten proteinen
EA200700917A1 (ru) Способ рефолдинга рекомбинантных антител
AR038568A1 (es) Anticuerpos anti-a beta y su uso
EP1453850A4 (de) Egvii-endoglucanase und dafür codierende nukleinsäuren
DE60144145D1 (de) Subtilisin-variante
ATE317441T1 (de) Cathepsin-02-protease
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
MXPA04001547A (es) Proteina de leptina porcina, antisentido y anticuerpo.
TW200510450A (en) Soluble fragments of the SARS-CoV spike glycoprotein
DE60139544D1 (de) Veränderte, fluoreszierende proteine
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
ATE408631T1 (de) Chimäres protein welches eine intramolekulare chaperon-ähnliche sequenz enthält und dessen anwendung zur insulinproduktion
ATE316577T1 (de) Das goodpasture-antigen bindende protein
WO2002026929A3 (en) Kini-3 motor protein and methods for its use
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
DE60230627D1 (de) Ein fusionsprotein
WO2004053117A3 (en) Serine protease
WO2002062964A3 (en) Ap1 amine oxidase variants
WO2003022883A3 (de) Verwendung eines proteins zur herstellung eines medikaments zur stimulierung des angeborenen unspezifischen immunsystems
WO1999055885A3 (en) Novel serine protease capable of selective cleavage of insulin-like growth factor binding protein
WO2002038765A3 (en) Dna encoding bovine immunoglobulin a inducing protein and uses therefor
WO2003012120A3 (en) Lp354 mammalian secreted protein
EA200500624A1 (ru) Промотор для il-18bp, его получение и применение
ATE325873T1 (de) Androgenrezeptor-komplex assoziiertes protein
WO2002063009A8 (en) Lp mammalian proteins; related reagents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties